Mylan NV (NASDAQ:MYL)

During Friday’s Morning trade, Shares of Mylan NV (NASDAQ:MYL), inclined 11.22% to $48.00. The firm opened its current trade at $47.60, and as of now, it is trading at $47.60. The total volume traded for the day is 17.89M shares, as compared to its average daily volume of 9.07M shares. The stock is floating in a range of $46.48 - $49.03. The stock holds the market capitalization of $23.60B.

Mylan NV lost its $26 billion hostile bid for Perrigo Co. after a seven-month pursuit, a rare outcome in what shaped up to be one of the most bitter takeover battles in decades, according to WSJ

Mylan said Friday that about 40% of Perrigo’s shares were tendered in the offer. It needed at least 50% to take control of its smaller rival. The Wall Street Journal had stated Thursday night that Mylan was set to lose the bid. WSJ Report

Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)

Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH), gained 8.48% to $13.30, during its current trading session.

Amphastar Pharmaceuticals, Inc. (AMPH) stated results for the third quarter ended September 30, 2015.

For the three months ended September 30, 2015, the Company stated net revenues of $63.9 million, an improvement of 7% from $59.7 million for the third quarter of 2014.

During the quarter, net revenues of enoxaparin were $21.3 million, a decrease of 34% contrast to $32.0 million for the third quarter of 2014, due to lower average selling prices.

Other finished pharmaceutical product revenues were $36.6 million for the quarter, an improvement of 69% contrast to $21.7 million for the third quarter of 2014, which was primarily due to an improvement in sales of naloxone to $10.5 million from $3.7 million, as a result of raised unit volumes at higher average prices.

Sales of the Company’s insulin API products were $6.0 million for the quarter contrast to $6.0 million for the third quarter of 2014.

Cost of revenues were $46.3 million, or 72% of revenues, and $47.9 million, or 80% of revenues, for the three months ended September 30, 2015 and 2014, respectively, representing a decrease of $1.6 million, or 3%. Pricing declines in enoxaparin were offset by pricing improvements in other finished pharmaceutical products. These pricing trends together with lower average heparin material costs, led to the improvement in gross margins.

The Company stated a quarterly net loss of $3.0 million, or $0.07 per fully diluted share, for the three months ended September 30, 2015, contrast to a net loss of $5.4 million, or $0.12 per fully diluted share, for the same period in the preceding year. The Company stated an adjusted non-GAAP quarterly net loss of $0.3 million, or $0.01 per fully diluted share, for the three months ended September 30, 2015, contrast to adjusted non-GAAP net loss of $3.3 million, or $0.07 per fully diluted share, for the same period in the preceding year.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable and inhalation products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Steadymed Ltd (NASDAQ:STDY)

Finally, Shares of Steadymed Ltd (NASDAQ:STDY), higher 9.03%, and is now trading at $3.02.

SteadyMed Ltd. (STDY), declared recent developments and financial results for the third quarter ended September 30, 2015.

“SteadyMed continued to make noteworthyprogress in executing across several planned initiatives during and subsequent to the third quarter. As predictable, we recently began production of registration stability lots for our lead drug product candidate Trevyent(R), for the treatment of pulmonary arterial hypertension (PAH). We expect to have the complete Chemistry, Manufacturing and Controls (CMC) information, counting the requisite stability data to submit our New Drug Application (NDA) for Trevyent in the third quarter of 2016. To that end, we’ve also taken a proactive step towards clearing the patent landscape for Trevyent by filing an Inter Partes Review (IPR) to invalidate a patent held by United Therapeutics,” said Jonathan Rigby, President and Chief Executive Officer of SteadyMed. “In addition, building upon the positive results achieved in our recent pharmacokinetic clinical study, we are advancing development and further clinical evaluation of our SMT-201 At Home Patient Analgesia (AHPA) program, a combination of our PatchPump(R) technology and ketorolac, in 2016.”

SteadyMed recorded revenues of $0.4 million in the third quarter of 2015. The revenue represents amortization of the $3 million upfront payment made by Cardiome, in connection with the license of rights to Trevyent in Europe, the Middle East and Canada. SteadyMed did not record any revenues for the corresponding period a year earlier.

For the third quarter ended September 30, 2015, SteadyMed stated a net loss of $5.9 million, or $0.44 per share, contrast to a net loss of $5.2 million, or $11.95 per share for the third quarter ended September 30, 2014. The current quarter’s calculation of loss per share is based on 13,581,160 weighted-average shares outstanding, as compared to 501,970 outstanding shares in the preceding-year period.

Total operating expenses for the third quarter ended September 30, 2015 were $6.3 million, contrast to $4.7 million for the quarter ended September 30, 2014, driven by an improvement in research and development (R&D) and general and administrative (G&A) expenses.

SteadyMed Ltd., together with its partner, SteadyMed Therapeutics, Inc., operates as a specialty pharmaceutical company that focuses on the development and commercialization of therapeutic product candidates in orphan and other specialty markets. Its lead product candidate is Trevyent, which is under development for the treatment of pulmonary arterial hypertension.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.